Hypothesis

Epigenetic noise generated during the first S-phase after reprogramming induction acts as a stochastic catalyst that facilitates the erasure of repressive H3K9me3 marks at aging-associated loci, thereby narrowing the rejuvenation gap. Specifically, transient bursts of transcriptional activity increase local histone acetylation and nucleosome turnover, which, when coupled with DNA replication, dilutes inherited methyl marks and permits deposition of activating modifications. Enhancing this noise in a controlled manner—for example, by low‑dose HDAC inhibition or transient overexpression of a noisy transcriptional activator—should increase the proportion of iPSCs that achieve epigenetic age reset comparable to embryonic stem cells, whereas suppressing transcriptional bursting should preserve somatic epigenetic memory and elevate residual epigenetic age scores.

Testable Predictions

1. Increase noise → lower residual H3K9me3: Treating fibroblasts with a sub‑toxic dose of an HDAC inhibitor (e.g., 0.1 mM valproic acid) exclusively during the first 6 h post‑OSKM induction will reduce H3K9me3 ChIP‑seq signal at CpG islands associated with epigenetic age clocks (e.g., ELOVL2, FHL2) by >=30 % compared with DMSO controls, without altering OCT4/SOX2 binding kinetics.
2. Decrease noise → higher epigenetic age: Simultaneous expression of a dominant‑negative histone acetyltransferase (HAT‑DN) or treatment with a transcriptional elongation inhibitor (e.g., 5 µM DRB) during the same window will increase residual H3K9me3 at those loci and raise the DNAmAge of resul

Hypothesis

Age‑associated loss of AMPK activity stems from increased S‑glutathionylation of conserved cysteine residues on the AMPK γ subunit, which alters adenine‑nucleotide binding affinity and raises the AMP/ADP activation threshold. This post‑translational modification is tissue‑specifically countered by glutaredoxin (Grx) enzymes, explaining why oxidative muscle fibers retain higher basal AMPK Thr172 phosphorylation despite similar upstream kinase levels. Restoring Grx activity in aged tissues should lower the AMPK activation threshold, rescue autophagy, and extend healthspan.

Mechanistic Reasoning

• The AMPK γ subunit contains cysteine‑rich CBS domains that sense AMP/ADP. S‑glutathionylation of these cysteines adds a bulky glutathione moiety, sterically hindering nucleotide pocket access and decreasing sensitivity to activating nucleotides.
• Oxidative fibers exhibit higher basal ROS, yet maintain elevated AMPK Thr172‑P. We propose they also express higher levels of glutaredoxin‑1 (Grx1) or glutaredoxin‑2 (Grx2), which rapidly de‑glutathionylate the γ subunit, keeping AMPK poised for activation.
• In glycolytic fibers, lower Grx expression permits accumulation of γ‑subunit glutathionylation with age, shifting the AMP/ADP EC50 upward and requiring stronger energetic stress (e.g., higher exercise intensity) to achieve comparable AMPK activation.
• Brain AMPK, supported by robust CaMKKβ expression, may also rely on local Grx systems to maintain sensitivity; age‑related decline in neuronal Grx could blunt central AMPK signaling and disrupt systemic longevogenic cue

Hypothesis

Emodin, through inhibition of EGFR/MAPK and STAT3 signaling, reduces the expression of the anti‑apoptotic Bcl‑2 family members Bcl‑xL and MCL‑1 in senescent cells, thereby lowering the threshold for BCL‑2 family inhibition. When combined with a sub‑lethal dose of the Src/BCL‑2 inhibitor dasatinib, this priming triggers selective apoptosis of senescent cells while sparing proliferating counterparts.

Mechanistic rationale

1. EGFR/MAPK‑STAT3 axis controls Bcl‑xL/MCL‑1 transcription – In cancer cells, emodin suppresses STAT3 phosphorylation and sensitises cells to EGFR‑TKIs (emodin suppresses Stat3 phosphorylation and sensitizes cells to EGFR‑TKIs). STAT3 directly drives transcription of Bcl‑xL and MCL‑1, proteins that sequester pro‑apoptotic BH3‑only molecules and block mitochondrial outer‑membrane permeabilization (MOMP). By attenuating STAT3 activity, emodin diminishes this survival shield.

2. EGFR inhibition reduces Src family kinase activity – EGFR signaling feeds into Src kinases that phosphorylate and inactivate the pro‑apoptotic protein BAD. Emodin‑mediated EGFR downregulation (emodin inhibits M1 macrophage activation via EGFR/MAPK pathway) consequently increases BAD activity, further tilting the Bcl‑2 rheostat toward apoptosis.

3. CDK4/6‑Rb pathway modulation – Emodin induces S/G2‑M arrest via downregulation of cyclin A/D1 and CDK2 ([emodin arrests cells and downregulates CDK2/cyclin A](https://www.tandfonline.com/doi/full/10.1080/13510002.

Hypothesis: Pulsatile AMPK Activation Reprograms Chronic Senescent Cells into Transient Hostage Negotiators via a SASP Switch

Core Idea

Chronic senescence arises when the hostage‑negotiator function of senescent cells is locked in a maladaptive state, perpetuating a proinflammatory SASP that drives inflammaging. We hypothesize that intermittent, tissue‑targeted activation of AMPK can flip the SASP from an NF‑κB‑driven, IL‑1β/TNF‑α‑rich profile to a p53‑dependent, pro‑regenerative mix (e.g., TGF‑β, IGF‑1, amphiregulin) without abolishing the cell‑cycle arrest. This would restore the negotiator’s ability to restrain neighboring proliferation while preventing the spread of chronic inflammation.

Mechanistic Rationale

AMPK phosphorylates two key nodes that dictate the senescent phenotype:

1. p53‑Ser15 – stabilizes p53, enforcing a durable G1 arrest that is compatible with tissue repair.5
2. ULK1‑Ser555 – initiates autophagy‑lysosomal flux, which degrades damaged mitochondria and limits ROS‑mediated NF‑κB activation.4 When AMPK is activated pulsatily, the autophagy burst is sufficient to clear ROS but not sustained enough to trigger compensatory feedback that reactivates NF‑κB. Concurrently, the transient p53 pulse favors transcription of SASP components that are under p53‑promoter control (e.g., TGF‑β, PAI‑1) while the brief NF‑κB window fails to establish the autocrine IL‑1α/IL‑1β loop that locks senescence into a chronic state.[4](https://pubmed.ncbi.nlm.

Hypothesis

Aged immune cells export mitochondrial ROS‑laden extracellular vesicles (EVs) that deliver oxidative mtDNA and oxidized lipids to hematopoietic stem cells (HSCs). This transfer induces epigenetic rewiring—specifically, loss of H3K27me3 at promoters of myeloid‑biased genes and gain of H3K4me3 at inflammatory cytokine loci—thereby skewing HSC output toward pro‑inflammatory myeloid lineages and fostering clonal hematopoiesis of indeterminate potential (CHIP). The resulting influx of inflammatory monocytes/macrophages amplifies inflammaging and SASP production in peripheral tissues, creating a self‑reinforcing loop where immune‑derived EVs both cause and exacerbate HSC dysfunction.

Mechanistic Rationale

1. Mitochondrial ROS as EV cargo – Senescent T cells and macrophages exhibit heightened mitochondrial ROS that oxidizes mtDNA and lipids, which are selectively packaged into EVs (exosomes and microvesicles) [7].
2. EV uptake by HSCs – Circulating EVs preferentially bind to HSCs via phosphatidylserine receptors, delivering oxidized mtDNA that activates cytosolic cGAS‑STING signaling, leading to NF‑κB activation and downstream epigenetic modifiers (e.g., DNMT3A, TET2) [2].
3. Epigenetic re‑programming – Chronic cGAS‑STING/NF‑κB signaling recruits histone‑acetyltransferases (p300/CBP) to myeloid gene promoters while recruiting PRC2 antagonists to lymphoid loci, locking in a myeloid‑biased transcriptional program [5].
4. Clonal expansion – Epigenetically primed HSCs exhibit increased self‑renewal and myeloid differentiation, providing a selective ad

Hypothesis

Senescent osteocytes act as a transient sink for osteoclastogenic signals by upregulating osteoprotegerin (OPG) in response to DNA damage, thereby tempering SASP-driven bone resorption. Clearance of these cells removes this protective OPG source, causing a short‑term rise in the RANKL/OPG ratio and a burst of osteoclast activity before the net anti‑resorptive benefit of senolysis appears.

Rationale

• Senescent cells exhibit a persistent DNA damage response that activates p53, which can transcriptionally upregulate OPG (see p53‑OPG link).
• In vitro, conditioned media from senescent osteoblasts shows mixed effects: while IL‑6 and TNF‑α promote osteoclastogenesis, added OPG neutralizes this effect (see OPG rescue).
• Age‑related bone loss correlates with a declining OPG/RANKL ratio in serum (see OPG decline).
• Minority mitochondrial outer membrane permeabilization (miMOMP) in senescence can release cytochrome c, which may act as a secondary messenger to boost OPG expression via caspase‑mediated cleavage of transcriptional co‑repressors (hypothetical link).

Predictions

1. In aged mice, serum OPG levels will rise modestly with accumulating senescent osteocytes, inversely correlating with TRAP‑positive osteoclast numbers.
2. Acute administration of a senolytic (e.g., dasatinib +  quercetin) will produce a biphasic OPG curve: an initial drop within 24 h followed by a gradu

Hypothesis

Aged tissues exhibit spatially confined senescence-associated secretory phenotype (SASP) gradients that directly modulate extracellular matrix (ECM) stiffness through integrin‑mediated mechanotransduction, creating a self‑reinforcing loop that accelerates functional decline.

Rationale

• Single‑cell and bulk transcriptomics have shown increased SASP factor expression in aged tissues, but spatial context remains unclear.
• Emerging expansion‑based methods like Seq‑Scope‑X now enable subcellular resolution mapping of transcripts in complex tissues Recent hypothesis on waste disposal.
• Prior work links senescent cell accumulation to altered tissue mechanics in skeletal muscle regeneration and neurodegenerative settings Frontiers in Aging Neuroscience and PMC9135953.

We propose that SASP components such as IL‑6, TGF‑β1, and MMPs are not uniformly secreted; instead, they form steep concentration gradients emanating from senescent cell clusters. These gradients engage mechanosensitive integrins on neighboring fibroblasts and epithelial cells, triggering focal adhesion kinase (FAK) signaling and downstream actin‑cytoskeletal remodeling. The resulting increase in actomyosin contractility elevates local ECM crosslinking and deposition, which in turn amplifies integrin activation—a positive feedback loop that propagates stiffness outward from the senescence niche

Hypothesis

Rapamycin extends lifespan not by systemic damage repair but by selectively suppressing enterochromaffin (EC) cell‑derived serotonin, thereby generating a localized gut‑derived famine signal that triggers intestinal epithelial autophagy and downstream metabolic re‑programming.

Mechanistic Rationale

• mTORC1 inhibition in EC cells reduces TPH1 activity and serotonin release [2][3].
• Loss of luminal 5‑HT relieves its inhibitory tone on AKT/mTOR in neighboring epithelial cells [4], paradoxically allowing a low‑level AMPK activation that stimulates ULK1‑dependent autophagy.
• Autophagic flux in enterocytes enhances barrier integrity, reduces inflammaging, and shifts microbiota toward SCFA producers [5], which further feeds back to sustain low serotonin via SCFA‑mediated TPH1 repression [3].
• The resulting gut‑centric signal mimics nutrient scarcity without systemic caloric restriction, explaining why rapamycin preserves some metabolic benefits of CR while diverging on immune outcomes [6].

Testable Predictions

1. EC‑specific TPH1 overexpression in mice treated with rapamycin will abolish the lifespan extension seen with rapamycin alone.
2. **Intestinal epithelial autophag

Hypothesis

Core proposition: Age-associated senescence of follicular dendritic cells (FDCs) reduces CXCL13 production, which limits B cell entry and survival in germinal centers (GCs) and thereby lowers activation-induced cytidine deaminase (AID) expression extrinsically. Although aged B cells retain the intrinsic ability to differentiate into plasma cells and proliferate when stimulated in vitro 3, the aged microenvironment fails to deliver the CD40L, IL-21 and BAFF signals that sustain AID and sustain somatic hypermutation (SHM) 2. This failure is amplified by B cell-intrinsic insulin receptor signaling, which drives a senescent phenotype in FDCs via exosomal miR-155 transfer, creating a feedback loop that further depresses CXCL13 and GC output 4.

Mechanistic rationale

1. FDC CXCL13 decline – Aging lowers FDC numbers and disrupts follicle architecture 2. CXCL13 is the chief chemokine that pulls CXCR5+ B cells into the GC light zone; less CXCL13 means fewer B cells receive tonic BCR and CD40 signals that induce AID via NF-κB and IRF4 pathways.

2. B cell insulin receptor (InsR) signaling – In aged mice, B cells show heightened InsR activity that correlates with CD4 T cell dysfunction 4. We propose that InsR activation increases sec

Hypothesis

The metabolic improvement seen during somatopause stems not from lower circulating IGF‑1 but from a GH‑dependent re‑routing of IGF‑1 signaling from an endocrine to a muscle‑autocrine mode. High GH drives hepatic production of IGF‑binding protein‑1 (IGFBP‑1) and suppressor of cytokine signaling‑2 (SOCS2), which sequester IGF‑1 in the bloodstream and blunt its action in skeletal muscle. When GH declines with age, hepatic IGFBP‑1 and SOCS2 fall, freeing IGF‑1 to act locally in muscle where it stimulates GLUT4 translocation via an AMPK‑independent PI3K‑Akt cascade, thereby enhancing glucose uptake without raising systemic IGF‑1 levels. This shift explains why GH deficiency extends lifespan more robustly than IGF‑1 reduction and why IGF‑1 can still improve insulin sensitivity despite low circulating concentrations.

Testable Predictions

1. In aged mice, pharmacologic GH antagonism will decrease liver IGFBP‑1 and SOCS2 mRNA (measured by qPCR) while increasing IGF‑1 mRNA and protein specifically in gastrocnemius muscle, without altering serum IGF‑1.
2. Muscle‑specific IGF‑1 receptor knockout will abolish the glucose‑tolerance improvement caused by GH antagonism, whereas liver‑specific IGF‑1R knockout will have little effect.
3. Administering recombinant IGFBP‑1 to GH‑antagonized aged mice will restore circulating IGF‑1 sequestration and blunt the metabolic benefit, re‑inducing insulin resistance.
4. In post‑menopausal women, short‑term GH receptor blockade will lower serum IGFBP‑1 and SOCS2, increase intramuscular IGF‑1 (detected by microdialysis), and improve o

Hypothesis

Pain tolerance reflects the mitochondrial reactive oxygen species (ROS) burden in innate immune cells that drives NLRP3 inflammasome activation, thereby linking subjective pain experience to systemic inflammaging and epigenetic age.

Mechanistic Rationale

• Mitochondrial dysfunction in monocytes and macrophages increases ROS production, which oxidizes mitochondrial DNA and triggers NLRP3 inflammasome assembly (see [8] and [4]).
• Active NLRP3 caspase‑1 cleaves pro‑IL‑1β and pro‑IL‑18, releasing cytokines that sensitize nociceptors and lower pain thresholds ([3],[7]).
• Chronic low‑grade inflammasome activity fuels the inflammation‑senescence cycle, accelerating epigenetic clocks ([1],[2],[5],[9]).
• Parasympathetic vagal tone inhibits NLRP3 via the cholinergic anti‑inflammatory pathway; reduced vagal activity (low HRV) removes this brake, amplifying the ROS‑inflammasome‑pain axis.

Thus, individuals with high pain sensitivity are expected to exhibit elevated mitochondrial ROS in circulating immune cells, heightened caspase‑1 activity, higher plasma IL‑1β/IL‑18, lower HRV, and advanced DNAmGrimAge.

Testable Predictions

1. Cross‑sectional – In a cohort of adults aged 40‑80, pain pressure threshold (PPT) will negatively correlate with mitochondrial ROS measured by MitoSOX fluorescence in PBMCs (r < ‑0.4, p < 0.01) and positively correlate with caspase‑1 activity (r > 0.3, p < 0.01).

Hypothesis

Personalized prebiotic supplementation designed to amplify endogenous GABA‑producing bacteria, as identified by fecal metagenomic quantification of glutamate decarboxylase (GAD) genes, will lead to a statistically significant greater reduction in anxiety symptoms (measured by GAD‑7) after 8 weeks compared with a standard dose of the GABA‑producing probiotic Lactiplantibacillus plantarum Lp815, and this effect will be mediated by increased fecal and plasma GABA concentrations.

Rationale

• The probiotic trial shows that exogenous Lp815 raises urinary GABA and improves anxiety scores, but relies on transient colonization of an introduced strain [1].
• Endogenous GABA‑producing microbes (e.g., certain Lactobacillus, Bifidobacterium, and Bacteroides species) possess GAD pathways that can be up‑regulated by specific fermentable substrates such as galacto‑oligosaccharides (GOS) or fructooligosaccharides (FOS).
• Metagenomic profiling of GAD abundance provides a functional biomarker that predicts which individuals harbor sufficient capacity for GABA synthesis when supplied with the appropriate prebiotic.
• Amplifying resident strains may yield more stable, long‑term GABA production than short‑lived probiotic engraftment, thereby enhancing downstream vagal signaling and central GABAergic tone.

Predictions

1. Participants with baseline fecal GAD gene copies above the cohort median will show a >30 % reduction in GAD‑7 scores after receiving the personalized prebiotic, whereas those below the median will show minimal change.
2. The personalized prebiotic group

Hypothesis

Mitochondrial NAD+ depletion in aged intestinal epithelial cells initiates tight junction disassembly independent of microbiome composition, thereby triggering systemic inflammaging.

Mechanistic Rationale

Aging is associated with a progressive decline in cellular NAD+ levels, particularly in tissues with high metabolic demand such as the gut epithelium [3]. NAD+ is a essential cofactor for sirtuin enzymes (SIRT1, SIRT3) that regulate mitochondrial function, oxidative stress responses, and the stability of tight junction proteins through deacetylation of zonula occludens-1 (ZO-1) and occludin [1]. When NAD+ falls, SIRT1 activity diminishes, leading to hyperacetylation of ZO-1 and occludin, which promotes their internalization and degradation at the apical membrane. This process increases paracellular permeability before any measurable shift in microbial taxa occurs.

Elevated permeability allows translocation of microbial products (LPS, peptidoglycan) and host-derived metabolites (advanced glycation end‑products like CML) into the lamina propria and circulation, activating innate immune receptors on macrophages and endothelial cells. The resulting cytokine surge (IL-6, TNF‑α) fuels systemic inflammaging and can further suppress epithelial NAD+ synthesis via CD38 upregulation, creating a feed‑forward loop.

Testable Predictions

1. Restoring epithelial NAD+ will preserve barrier integrity despite an aged microbiome.
   • Experiment: Treat aged mice with an intestine‑targeted NAD+ precursor (e.g., nicotinamide riboside conjugated to a gut‑restri

Hypothesis

In aged gut microbiota, increased production of secondary bile acids (e.g., deoxycholic acid) activates the nuclear receptor FXR in enteric neurons, which transcriptionally upregulates Rubicon and stimulates mTORC1 via SREBP-1c–dependent lipid signaling, thereby suppressing autophagy as a protective response to limit neuronal excitability. Chronic FXR activation locks autophagy in a suppressed state, leading to accumulation of damaged proteins and organelles, contributing to enteric neuropathy and motility decline.

Testable Predictions

1. Pharmacological or genetic inhibition of FXR in aged mice will restore neuronal autophagy markers (LC3‑II, p62 degradation) and improve gut motility.
2. FXR activation in young enteric neurons (via agonist or bile acid supplementation) will recapitulate the aged phenotype: increased Rubicon, mTORC1 hyperactivity, reduced autophagosome formation, and heightened susceptibility to oxidative stress.
3. Depleting gut microbiota or bile acid synthesis (e.g., antibiotics, cholestyramine) in aged animals will lower FXR activity, decrease Rubicon expression, and rescue autophagy without altering mTORC1 upstream nutrients.
4. FXR will bind directly to the Rubicon promoter in enteric neurons; ChIP‑qPCR will show enriched FXR occupancy that increases with age.

Mechanistic Rationale

FXR is a bile acid‑activated receptor known to regulate lipid homeostasis and inflammation. In hepatocytes, FXR activation can increase mTORC1 signaling via SREBP-1c–mediated phospholipid synthesis that enriches lysosomal membranes, facilitating Rag GT

Hypothesis

Circadian-driven rhythmic inhibition of histone deacetylases by microbiome‑derived butyrate maintains youthful epigenetic states in colonic epithelial stem cells through timed deposition of H3K4me3 at proliferation‑associated loci. Loss of this rhythm accelerates epigenetic age and predisposes to neoplastic transformation.

Rationale

• The core clock complex CLOCK:BMAL1 recruits histone methyltransferases MLL1/3 to catalyze H3K4me3, linking circadian timing to active chromatin states [2].
• Butyrate, a microbial short‑chain fatty acid, inhibits HDACs and enhances Per2 expression via chromatin remodeling, thereby reinforcing circadian amplitude [6].
• Age‑related promoter hypermethylation silences Bmal1, disrupting the clock and its epigenetic output [3].
• In colon, epigenetic age acceleration correlates with cancer risk and consensus molecular subtypes, indicating that the clock reflects rather than merely tracks biological aging [7].

Combining these points, we propose that butyrate‑mediated HDAC inhibition creates a daily window of heightened histone acetyltransferase activity that enables CLOCK:BMAL1‑MLL1/3 to deposit H3K4me3 in a circadian‑gated fashion. When this window is mistimed or blunted, stem‑cell niches lose periodic H3K4me3 renewal, leading to stochastic epigenetic drift d

Hypothesis

We propose that a gonad‑derived signal, analogous to GDF11 but acting specifically on the lysosomal transcription factor TFEB, actively suppresses TFEB nuclear translocation during early adulthood to prioritize lysosomal biogenesis for vitellogenesis and oocyte maturation. This suppression reduces autophagic flux, conserving nucleotides and amino acids for reproduction. After the reproductive window, the signal wanes, allowing TFEB to resume its homeostatic role, but the preceding period of low autophagy causes irreversible damage that manifests as aging. Thus, autophagy decline is not a passive by‑product of damage but an antagonistically pleiotropic program that trades early‑life fecundity for late‑life survival.

Mechanistic Basis

• Early‑life gonadotropins (LH/FSH) stimulate somatic gonads to secrete a peptide we term Repro‑Lysin (RL). RL binds a membrane receptor on peripheral tissues, activating the MAPK‑ERK pathway, which phosphorylates TFEB at serine‑122, promoting its binding to 14‑3‑3 proteins and cytoplasmic retention.
• Cytoplasmic TFEB fails to activate CLEAR network genes (ATG5, ATG7, BECN1, lysosomal proteases), lowering autophagosome formation and lysosomal acidification.
• The same RL‑ERK axis also up‑regulates MITF and TFE3, diverting lysosomal resources toward melanin and yolk protein deposition, directly supporting oocyte vitellogenesis.
• When gonadal output declines post‑reproduction, RL levels fall, ERK activity diminishes, TFEB is dephosphorylated by calcineurin, translocates to the nucleus, and restores CLEAR expression—but the

Hypothesis

Short, repeatable mRNA‑OSKM delivery, when synchronized with a pulsed NAD⁺‑boosting regimen, activates a PGC‑1α‑dependent mitochondrial repair pathway that uncouples epigenetic age reduction from pluripotency entry and produces organ‑specific rejuvenation without tumor formation.

Rationale

• Partial reprogramming with transient OSKM expression reverses epigenetic age while preserving somatic identity, yet the optimal delivery mode remains undefined. Viral vectors risk integration; chemical cocktails lack precise temporal control. mRNA offers transient, dose‑controllable exposure but has been minimally tested in vivo [3].
• Recent work shows that brief OSKM exposure can stimulate PGC‑1α independently of HIF‑1α‑mediated hypoxia, linking nuclear reprogramming to mitochondrial metabolism (see Front. Cell. Neurosci. 2022).
• NAD⁺ elevation enhances PGC‑α activity and improves mitochondrial fidelity, a manipulation that extends lifespan in model organisms [5]. Combining these two signals may amplify the mitochondrial repair arm of partial reprogramming while keeping the pluripotency trajectory minimal.
• Tissue‑specific responses to OSKM vary, suggesting that metabolic state influences reprogramming outcomes [6]. A NAD⁺ pulse could shift the cellular redox environment, biasing OSKM‑induced transcription toward metabolic rather than stemness programs in a context‑dependent manner.

Predictions

1. Mice receiving cyclic mRNA‑OSKM (4‑day pulses every 28 days) plus intermittent NAD⁺ booster (e.g., nicotinamide riboside 400 mg/kg i.p. 24 h before each OSKM pulse) w

Hypothesis

In aged erythroid progenitors, chronic autophagy activated by niche‑derived inflammation selectively degrades the EPO receptor (EPOR) and associated JAK2/STAT5 signaling proteins, producing functional EPO resistance that contributes to age‑related anemia.

Mechanistic Basis

Aged bone marrow stromal cells exhibit mTORC1 hyperactivation (phospho‑ULK1 Ser757) that suppresses autophagy, raises mitochondrial ROS, and secretes IL‑6/TNF‑α (1, 2, 3). These cytokines engage JAK/STAT and NF‑κB pathways in erythroid progenitors, leading to FoxO3 activation and upregulation of autophagy initiators (ULK1 Ser317/777) despite declining AMPK activity (4). Simultaneously, oxidative stress promotes phosphorylation of EPOR on Tyr residues, creating a degron recognized by selective autophagy receptors such as p62/SQSTM1 and NBR1. Consequently, EPOR‑JAK2 complexes are sequestered into autophagosomes and degraded, attenuating STAT5 phosphorylation and reducing erythroid survival and proliferation signals.

Testable Predictions

1. Aged erythroid progenitors will show increased LC3‑II/LC3‑I ratio and higher colocalization of EPOR with autophagosomes compared with young cells.
2. Pharmacological inhibition of autophagy (chloroquine or bafilomycin A1) or genetic ablation of Atg7 in the erythroid lineage will restore EPOR prote